Zein: Potential biopolymer in inflammatory bowel diseases
Source abstract
Abstract
Abstract Effectively managing inflammatory bowel disease (IBD) poses difficulties due to its persistent nature and unpredictable episodes of exacerbation. There is encouraging evidence that personalized medication delivery systems can improve therapy efficacy while reducing the negative effects of standard medicines. Zein, a protein produced from corn, has garnered interest as a possible means of delivering drugs for the treatment of IBD. This review delves into Zein‐based drug delivery systems, showcasing its biodegradability, controlled release capabilities, and biocompatibility. Studies have shown that Zein‐based nanoparticles, microcarriers, and core‐shell microparticles have the capacity to increase medication stability, enhance targeting in the intestines, and decrease toxicity in animal models of IBD. The review highlights the promise of Zein in personalized therapy for IBD and urges more study to enhance its clinical use.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Inflammatory Bowel Disease · Curcumin's Biomedical Applications · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad India
Gujarat Technological University, School of Pharmacy Gandhinagar Gujarat India
Dr. Dayaram Patel Pharmacy College Bardoli India
S. K. Patel College of Pharmaceutical Education and Research Ganpat University Kherva India
Faculty of Pharmacy Silpakorn University Nakhon Pathom Thailand
WAYMADE India Pvt. Ltd. Vadodara Gujarat India
Department of Pharmacy, School of Medical and Allied Sciences Galgotias University Noida Uttar Pradesh India
School of Pharmacy and Technology Management SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Hyderabad India
Funding
Faculté de pharmacie, Université de Montréal
References (65)
Show source-provided references
1. 10.2196/3285610.2196/32856 ↗
2. Ampersand Health · 2024
3. IBD.What is inflammatory bowel disease (IBD)?2022.
4. 10.1128/CMR.15.1.79-94.200210.1128/CMR.15.1.79-94.2002 ↗
5. 10.3390/ijms2402152610.3390/ijms24021526 ↗
6. 10.1016/S2468-1253(23)00154-110.1016/S2468-1253(23)00154-1 ↗
7. 10.1159/00052742210.1159/000527422 ↗
8. 10.3389/fmed.2021.76547410.3389/fmed.2021.765474 ↗
9. 10.1016/j.biomaterials.2022.12136410.1016/j.biomaterials.2022.121364 ↗
10. 10.3390/molecules2307162210.3390/molecules23071622 ↗
11. 10.1016/j.addr.2013.10.00110.1016/j.addr.2013.10.001 ↗
12. 10.1080/17425247.2023.228958610.1080/17425247.2023.2289586 ↗
13. 10.1007/s13233-022-0078-910.1007/s13233-022-0078-9 ↗
14. 10.3390/gels908064310.3390/gels9080643 ↗
15. 10.3390/polysaccharides303003710.3390/polysaccharides3030037 ↗
16. 10.3390/pharmaceutics1504131310.3390/pharmaceutics15041313 ↗
17. 10.1016/j.indcrop.2011.07.02210.1016/j.indcrop.2011.07.022 ↗
18. 10.1016/j.eurpolymj.2022.11139610.1016/j.eurpolymj.2022.111396 ↗
19. 10.1094/CCHEM.2000.77.6.72410.1094/CCHEM.2000.77.6.724 ↗
20. 10.1016/0378-1119(84)90093-310.1016/0378-1119(84)90093-3 ↗
21. 10.1021/jf048530s10.1021/jf048530s ↗
22. 10.1094/CCHEM-06-10-009110.1094/CCHEM-06-10-0091 ↗
23. 10.1016/j.jconrel.2014.06.03610.1016/j.jconrel.2014.06.036 ↗
24. 10.1016/j.biomaterials.2003.10.08410.1016/j.biomaterials.2003.10.084 ↗
25. 10.1016/j.jcs.2007.08.00410.1016/j.jcs.2007.08.004 ↗
26. 10.1016/j.eurpolymj.2022.11155710.1016/j.eurpolymj.2022.111557 ↗
27. 10.1016/j.ijbiomac.2024.12941610.1016/j.ijbiomac.2024.129416 ↗
28. 10.1007/s00249-003-0354-310.1007/s00249-003-0354-3 ↗
29. 10.1016/S0021-9258(18)33974-710.1016/S0021-9258(18)33974-7 ↗
30. 10.1016/S0167-4838(96)00212-910.1016/S0167-4838(96)00212-9 ↗
31. 10.1016/j.jcs.2004.12.00510.1016/j.jcs.2004.12.005 ↗
32. 10.1016/j.bbapap.2006.04.00210.1016/j.bbapap.2006.04.002 ↗
33. 10.1016/j.foodchem.2015.03.00910.1016/j.foodchem.2015.03.009 ↗
34. 10.3389/fphar.2023.112025110.3389/fphar.2023.1120251 ↗
35. 10.1016/S0926-6690(00)00064-910.1016/S0926-6690(00)00064-9 ↗
36. 10.1016/j.ejpb.2008.01.00610.1016/j.ejpb.2008.01.006 ↗
37. 10.1016/j.powtec.2017.01.03810.1016/j.powtec.2017.01.038 ↗
38. 10.1016/j.jcis.2007.11.05810.1016/j.jcis.2007.11.058 ↗
39. 10.1016/j.actbio.2020.10.01510.1016/j.actbio.2020.10.015 ↗
40. 10.1016/j.ijbiomac.2023.12889210.1016/j.ijbiomac.2023.128892 ↗
41. 10.1016/j.ijpharm.2019.01.06610.1016/j.ijpharm.2019.01.066 ↗
42. 10.1007/s13346-023-01365-010.1007/s13346-023-01365-0 ↗
43. 10.1007/s12247‐022‐09663‐910.1007/s12247‐022‐09663‐9 ↗
44. 10.3390/vaccines1103066110.3390/vaccines11030661 ↗
45. 10.3390/pharmaceutics1411241710.3390/pharmaceutics14112417 ↗
46. 10.3390/pharmaceutics1505143510.3390/pharmaceutics15051435 ↗
47. Nanotherapeutics in tumour microenvironment for cancer therapy
48. 10.2174/221173851066622042611534010.2174/2211738510666220426115340 ↗
49. 10.3390/pharmaceutics1502060810.3390/pharmaceutics15020608 ↗
50. 10.1615/CritRevTherDrugCarrierSyst.202204308510.1615/CritRevTherDrugCarrierSyst.2022043085 ↗
51. 10.1007/978‐3‐031‐14100‐3_610.1007/978‐3‐031‐14100‐3_6 ↗
52. 10.1007/978‐3‐031‐39020‐3_410.1007/978‐3‐031‐39020‐3_4 ↗
53. 10.1201/9781003322368-810.1201/9781003322368-8 ↗
54. 10.1016/j.drudis.2024.10406010.1016/j.drudis.2024.104060 ↗
55. 10.1016/j.jddst.2024.10561210.1016/j.jddst.2024.105612 ↗
56. 10.1016/B978-0-443-15491-1.00010-910.1016/B978-0-443-15491-1.00010-9 ↗
57. 10.1021/acs.iecr.8b0209210.1021/acs.iecr.8b02092 ↗
58. 10.1021/acsami.1c0980410.1021/acsami.1c09804 ↗
59. 10.1186/s13020-021-00449-810.1186/s13020-021-00449-8 ↗
60. 10.1016/j.matdes.2022.11089410.1016/j.matdes.2022.110894 ↗
61. 10.1002/advs.20220741810.1002/advs.202207418 ↗
62. 10.1039/D1FO02493K10.1039/D1FO02493K ↗
63. 10.3390/pharmaceutics1412283010.3390/pharmaceutics14122830 ↗
64. 10.3389/fchem.2022.98105510.3389/fchem.2022.981055 ↗
65. 10.1021/acs.biomac.1c0123310.1021/acs.biomac.1c01233 ↗